Charani Ranasinghe

Summary

Affiliation: Australian National University
Country: Australia

Publications

  1. ncbi A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations
    Charani Ranasinghe
    The John Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia
    Vaccine 29:3008-20. 2011
  2. ncbi Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1
    Charani Ranasinghe
    Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Canberra, ACT 2601, Australia
    Vaccine 24:5881-95. 2006
  3. ncbi Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity
    Charani Ranasinghe
    The Emerging Pathogens and Vaccines Program, The John Curtin School of Medical Research, The Australian National University, ACT, Australia
    Expert Rev Vaccines 8:1171-81. 2009
  4. ncbi Mucosal HIV-1 pox virus prime-boost immunization induces high-avidity CD8+ T cells with regime-dependent cytokine/granzyme B profiles
    Charani Ranasinghe
    Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Canberra, Australia
    J Immunol 178:2370-9. 2007
  5. ncbi Immunisation route-dependent expression of IL-4/IL-13 can modulate HIV-specific CD8(+) CTL avidity
    Charani Ranasinghe
    The Australian National University, Canberra, Australia
    Eur J Immunol 39:1819-30. 2009
  6. ncbi 4-1BBL coexpression enhances HIV-specific CD8 T cell memory in a poxvirus prime-boost vaccine
    Jodie M Harrison
    Department of Immunology and Genetics, The John Curtin School of Medical Research, Canberra City, Australia
    Vaccine 24:6867-74. 2006
  7. ncbi Evaluating vaccinia virus cytokine co-expression in TLR GKO mice
    Duncan B Sutherland
    Emerging Pathogens and Vaccines Program, The John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
    Immunol Cell Biol 89:706-15. 2011
  8. ncbi Differential effects of the type I interferons alpha4, beta, and epsilon on antiviral activity and vaccine efficacy
    Stephanie L Day
    Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
    J Immunol 180:7158-66. 2008
  9. ncbi Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use
    Scott A Thomson
    Division of Immunology and Genetics, John Curtin School of Medical Research JCSMR, Australian National University, P O Box 334, Canberra, ACT 2601, Australia
    Vaccine 23:4647-57. 2005
  10. ncbi Human immunodeficiency virus-1 vaccine design: where do we go now?
    Danushka K Wijesundara
    Department Emerging Pathogens and Vaccines, The John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory, Australia
    Immunol Cell Biol 89:367-74. 2011

Collaborators

Detail Information

Publications12

  1. ncbi A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations
    Charani Ranasinghe
    The John Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia
    Vaccine 29:3008-20. 2011
    ..Our findings further substantiate the importance of vector selection/combination, order and route of delivery when designing effective vaccines for HIV-1...
  2. ncbi Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1
    Charani Ranasinghe
    Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Canberra, ACT 2601, Australia
    Vaccine 24:5881-95. 2006
    ....
  3. ncbi Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity
    Charani Ranasinghe
    The Emerging Pathogens and Vaccines Program, The John Curtin School of Medical Research, The Australian National University, ACT, Australia
    Expert Rev Vaccines 8:1171-81. 2009
    ....
  4. ncbi Mucosal HIV-1 pox virus prime-boost immunization induces high-avidity CD8+ T cells with regime-dependent cytokine/granzyme B profiles
    Charani Ranasinghe
    Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Canberra, Australia
    J Immunol 178:2370-9. 2007
    ..A greater understanding of these factors will be crucial for the development of effective vaccines in the future...
  5. ncbi Immunisation route-dependent expression of IL-4/IL-13 can modulate HIV-specific CD8(+) CTL avidity
    Charani Ranasinghe
    The Australian National University, Canberra, Australia
    Eur J Immunol 39:1819-30. 2009
    ..STAT6(-/-) mice also showed memory CTL of higher avidity. Furthermore, CCL5 expression in K(d)Gag(197-205)-specific CTL was also regulated by IL-4/IL-13...
  6. ncbi 4-1BBL coexpression enhances HIV-specific CD8 T cell memory in a poxvirus prime-boost vaccine
    Jodie M Harrison
    Department of Immunology and Genetics, The John Curtin School of Medical Research, Canberra City, Australia
    Vaccine 24:6867-74. 2006
    ..This data is the first to show modulation of the immune response to a viral vaccine by coexpression of 4-1BBL and supports this strategy as an exciting approach for enhancement of T cell memory in prime-boost vaccines...
  7. ncbi Evaluating vaccinia virus cytokine co-expression in TLR GKO mice
    Duncan B Sutherland
    Emerging Pathogens and Vaccines Program, The John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
    Immunol Cell Biol 89:706-15. 2011
    ....
  8. ncbi Differential effects of the type I interferons alpha4, beta, and epsilon on antiviral activity and vaccine efficacy
    Stephanie L Day
    Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
    J Immunol 180:7158-66. 2008
    ..Our data also indicate that while IFN-epsilon exhibits certain biological traits similar to other type I IFNs, it may also have a specific role in mucosal immune regulation that is quite distinct...
  9. ncbi Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use
    Scott A Thomson
    Division of Immunology and Genetics, John Curtin School of Medical Research JCSMR, Australian National University, P O Box 334, Canberra, ACT 2601, Australia
    Vaccine 23:4647-57. 2005
    ..This platform strategy could be used for other infections and cancers where T cell responses are important for protection...
  10. ncbi Human immunodeficiency virus-1 vaccine design: where do we go now?
    Danushka K Wijesundara
    Department Emerging Pathogens and Vaccines, The John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory, Australia
    Immunol Cell Biol 89:367-74. 2011
    ....
  11. ncbi Prime-boost strategies in DNA vaccines
    C Jane Dale
    Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia
    Methods Mol Med 127:171-97. 2006
    ..Methods for the construction of the vaccines, the use of animal models, and the detection of immune responses are described...
  12. ncbi Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3
    Stephen J Kent
    Department of Microbiology and Immunology, University of Melbourne, VIC 3010, Australia
    Vaccine 23:5009-21. 2005
    ..Our data suggest strategies for effective priming of partial immunity to mucosal HIV-1 exposure utilizing systemic prime and mucosal boost vaccination strategies...